Literature DB >> 21306363

Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.

Marisa Elena Domino1, Bradley C Martin, Elizabeth Wiley-Exley, Shirley Richards, Abel Henson, Timothy S Carey, Betsy Sleath.   

Abstract

OBJECTIVE: To estimate the effect of two separate policy changes in the North Carolina Medicaid program: (1) reduced prescription lengths from 100 to 34 days' supply, and (2) increased copayments for brand name medications. DATA SOURCES/STUDY
SETTING: Medicaid claims data were obtained from the Centers for Medicare and Medicaid Services for January 1, 2000-December 31, 2002. STUDY
DESIGN: We used a pre-post controlled partial difference-in-difference-in-differences design to examine the effect of the policy change on adults in North Carolina; adult Medicaid recipients from Georgia served as controls. Outcomes examined include medication adherence and Medicaid expenditures. DATA COLLECTION/EXTRACTION
METHODS: Data were aggregated to the person-quarter level. Individuals in HMOs, nursing homes, pregnant, or deceased in the quarter were excluded. PRINCIPAL
FINDINGS: Both policies decreased medication adherence. The days' supply policy had a much larger effect on adherence than did the copayment increase. Total Medicaid spending declined from the days' supply policy, but the copayment policy resulted in a net increase in Medicaid expenditures.
CONCLUSIONS: Although Medicaid costs decreased with the change in days supply policy, these savings were due to reduced adherence to these chronic medications. Additional research should examine the effect of these policy changes from the perspective of Medicaid enrollees. © Health Research and Educational Trust.

Entities:  

Mesh:

Year:  2011        PMID: 21306363      PMCID: PMC3087836          DOI: 10.1111/j.1475-6773.2010.01237.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  30 in total

1.  COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.

Authors:  Rick A Weideman; Kevin C Kelly; Catherine L Kelley; Byron Cryer
Journal:  Am J Manag Care       Date:  2002-10       Impact factor: 2.229

2.  Drug affordability and prescription noncompliance in the United States: 1997-2002.

Authors:  Jae Kennedy; Joseph Coyne; David Sclar
Journal:  Clin Ther       Date:  2004-04       Impact factor: 3.393

3.  Restricting patients' medication supply to one month: saving or wasting money?

Authors:  Marisa Elena Domino; Joshua Olinick; Betsy Sleath; Sharman Leinwand; Patricia J Byrns; Tim Carey
Journal:  Am J Health Syst Pharm       Date:  2004-07-01       Impact factor: 2.637

4.  What does the RAND Health Insurance Experiment tell us about the impact of patient cost sharing on health outcomes?

Authors:  Michael E Chernew; Joseph P Newhouse
Journal:  Am J Manag Care       Date:  2008-07       Impact factor: 2.229

5.  Impact of medication adherence on hospitalization risk and healthcare cost.

Authors:  Michael C Sokol; Kimberly A McGuigan; Robert R Verbrugge; Robert S Epstein
Journal:  Med Care       Date:  2005-06       Impact factor: 2.983

6.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Authors:  A Gray; M Raikou; A McGuire; P Fenn; R Stevens; C Cull; I Stratton; A Adler; R Holman; R Turner
Journal:  BMJ       Date:  2000-05-20

7.  Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.

Authors:  Matthew S Keene; Michael T Eaddy; Winnie W Nelson; Matthew W Sarnes
Journal:  Am J Manag Care       Date:  2005-10       Impact factor: 2.229

8.  Rehospitalization risk with second-generation and depot antipsychotics.

Authors:  Robert R Conley; Deanna L Kelly; Raymond C Love; Robert P McMahon
Journal:  Ann Clin Psychiatry       Date:  2003-03       Impact factor: 1.567

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.

Authors:  Stephen B Soumerai
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

View more
  11 in total

1.  State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.

Authors:  Marisa Elena Domino; Christopher Alan Beadles
Journal:  Health Serv Outcomes Res Methodol       Date:  2014-06-01

2.  A National Assessment of Medication Adherence to Statins by the Racial Composition of Neighborhoods.

Authors:  Andrew M Davis; Michael S Taitel; Jenny Jiang; Dima M Qato; Monica E Peek; Chia-Hung Chou; Elbert S Huang
Journal:  J Racial Ethn Health Disparities       Date:  2016-06-28

3.  Impact of issuing longer- versus shorter-duration prescriptions: a systematic review.

Authors:  Sarah King; Céline Miani; Josephine Exley; Jody Larkin; Anne Kirtley; Rupert A Payne
Journal:  Br J Gen Pract       Date:  2018-03-12       Impact factor: 5.386

4.  Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa.

Authors:  Thomas Gaziano; Sylvia Cho; Stephen Sy; Ankur Pandya; Naomi S Levitt; Krisela Steyn
Journal:  Health Aff (Millwood)       Date:  2015-09       Impact factor: 6.301

Review 5.  Cost Sharing in Medicaid: Assumptions, Evidence, and Future Directions.

Authors:  Victoria Powell; Brendan Saloner; Lindsay M Sabik
Journal:  Med Care Res Rev       Date:  2015-11-24       Impact factor: 3.929

6.  Medication oversupply in patients with diabetes.

Authors:  Carolyn T Thorpe; Heather Johnson; Anna Legreid Dopp; Joshua M Thorpe; Katie Ronk; Christine M Everett; Mari Palta; David A Mott; Betty Chewning; Loren Schleiden; Maureen A Smith
Journal:  Res Social Adm Pharm       Date:  2014-09-11

7.  Evaluation of the chronic disease management program for appropriateness of medication adherence and persistence in hypertension and type-2 diabetes patients in Korea.

Authors:  Jung-Ae Kim; Eun-Sook Kim; Eui-Kyung Lee
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

8.  Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.

Authors:  Bander Balkhi; Monira Alwhaibi; Nasser Alqahtani; Tariq Alhawassi; Thamir M Alshammari; Mansour Mahmoud; Mansour Almetwazi; Sondus Ata; Khalid M Kamal
Journal:  BMJ Open       Date:  2019-07-23       Impact factor: 2.692

9.  Retrospective, multicohort analysis of the Clinical Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and prescriber time of issuing either short (<60 days) or long (≥60 days) prescription lengths in primary care for common, chronic conditions in the UK.

Authors:  Brett Doble; Rupert Payne; Amelia Harshfield; Edward C F Wilson
Journal:  BMJ Open       Date:  2017-12-04       Impact factor: 2.692

10.  Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis.

Authors:  Manjiri D Pawaskar; Liou Xu; Yuexin Tang; Gary A Puckrein; Swapnil N Rajpathak; Bruce Stuart
Journal:  Diabetes Ther       Date:  2018-08-24       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.